XASE
VNRX
Market cap2mUSD
Oct 08, Last price
0.22USD
1D
-2.92%
1Q
-83.75%
Jan 2017
-99.76%
IPO
-99.73%
Name
VolitionRX Ltd
Chart & performance
P/E
—
P/S
1.53
EPS
—
Div yield, %
—
Shrs. gr., 5y
18.73%
Rev. gr., 5y
164.15%
Revenues
2m
+40.04%
Net income
-23m
L-13.39%
CFO
-20m
L-23.98%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Key people
Timothy Still
Non-Executive Chairman of the Board · since 2024
Jasmine Kway
Chief Executive Officer of Singapore Volition · since 2018
Gaetan Michel
Chief Operating Officer · since 2021
Louise Batchelor
Group Chief Marketing and Communications Officer · since 2022
Jacob Micallef
Chief Scientific Officer · since 2015
Nicholas Plummer
Group General Counsel · since 2021
Terig Hughes
Chief Financial Officer, Treasurer · since 2021
Gael Forterre
Chief Commercial Officer · since 2021
Andrew Retter
Chief Medical Officer · since 2024
Rodney Rootsaert
Corporate Secretary · since 2011
President, Chief Executive Officer, Director · since 2011
Phillip Barnes
Independent Director · since 2019
Alan Colman
Independent Director · since 2011
Mickie Henshall
Independent Director · since 2022
Guy Innes
Independent Director · since 2024
Kim Nguyen
Independent Director · since 2021
Ethel Rubin
Independent Director · since 2024
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||